Entera Bio (ENTX) Free Cash Flow (2021 - 2026)

Entera Bio has disclosed Free Cash Flow across 6 years of filings, most recently posting -$3.1 million for Q1 2026.

• Quarterly Free Cash Flow fell 118.84% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.2 million (down 43.7% YoY) and the FY2025 annual result came in at -$7.5 million, down 9.62% from the prior year.
• Free Cash Flow slipped to -$3.1 million in Q1 2026, from -$1.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$1.3 million in Q2 2024 and troughed at -$4.8 million in Q1 2022.
• A 5-year average of -$2.2 million and a median of -$1.9 million in 2024 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow surged 66.36% — and 2026, when it tumbled 118.84%.
• Tracing ENTX's Free Cash Flow over 5 years: stood at -$2.0 million in 2022, then sank by 30.19% to -$2.6 million in 2023, then soared by 43.94% to -$1.5 million in 2024, then slipped by 26.53% to -$1.9 million in 2025, then tumbled by 66.13% to -$3.1 million in 2026.
• Business Quant data shows ENTX's Free Cash Flow at -$3.1 million in Q1 2026, -$1.9 million in Q4 2025, and -$2.5 million in Q3 2025.